One-month Clinical Evaluation of Oté Sensation Multi-Purpose Solution Care System

The purpose of this study is to evaluate the clinical performance of the contact lens care product Oté Sensation in a representative population of soft contact lens wearers. For comparison, a widely used FDA approved soft lens multipurpose solution will be used as a control. This control product has been tested in previous clinical trials.

Study Overview

• Status: Completed
• Conditions: Myopia; Hyperopia
• Intervention / Treatment: Device: Test solution; Device: Control solution

Detailed Description

This will be a 1-month, 200-subject, double-masked (care product), bilateral, randomized, comparative study. Subjects will be clinically evaluated at the initial baseline visit (Visit 1), then after 1 week and 1 month of lens wear having been randomly assigned to use one of six lens types and to either the test or control solutions.

• Study Type: Interventional
• Enrollment (Actual): 194
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United Kingdom
  • Berkshire
    • Reading, Berkshire, United Kingdom, RG1 1EX
      • Eyesite
  • Bournemouth
    • Poole, Bournemouth, United Kingdom, BH15 1AU
      • Leightons and Tempany
  • Bristol
    • Chew Magna, Bristol, United Kingdom, BS40 8PR
      • Brock and Houlford
  • Middlesex
    • Uxbridge, Middlesex, United Kingdom, UB8 1JX
      • Harrold Opticians
  • Pinner
    • Eastcote, Pinner, United Kingdom, HA5 1RJ
      • First Contact
  • Surrey
    • Farnham, Surrey, United Kingdom, GU9 7EN
      • Visioncare Research Ltd
• United States
  • Florida
    • Sarasota, Florida, United States, 34232
      • Golden Vision
  • Kansas
    • Pittsburg, Kansas, United States, 66762
      • Kannarr Eye Care
  • New York
    • Vestal, New York, United States, 13850
      • Sacco Eye Group
  • Tennessee
    • Memphis, Tennessee, United States, 38111
      • Optometry Group Pllc
  • Texas
    • Tyler, Texas, United States, 75703
      • Frazier Vision, Inc.

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Be a currently adapted soft contact lens wearer (>1 month of lens wear).
• Be at least 18 years of age.
• Refractive astigmatism <0.75 D in both eyes.
• Have clear corneas and be free of any anterior segment disorders.
• Be correctable through spherocylindrical refraction to 6/12 (20/40) (0.30 LogMAR) or better in each eye.
• Contact lens sphere requirement between +4.00 Dioptre and -8.00 D (inclusive).
• Require visual correction in both eyes (monovision allowed, no monofit).

• Have normal eyes with no evidence of abnormality or disease. For the purposes of this study a normal eye is defined as one having:

  1. No amblyopia
  2. No strabismus
  3. No evidence of lid abnormality or infection
  4. No conjunctival abnormality or infection that would contraindicate contact lens wear
  5. No clinically significant slit lamp findings (i.e. corneal staining, stromal edema, staining, scarring, vascularization, infiltrates or abnormal opacities)
  6. No other active ocular disease.

Exclusion Criteria:

• Require toric or multifocal contact lenses.
• Previously shown a sensitivity to any of the study solution components.
• Any systemic or ocular disease or allergies affecting ocular health.
• Using systemic or topical medications that will in the investigator's opinion affect ocular physiology or lens performance.
• Clinically significant (>Grade 3) corneal staining, corneal stromal edema, corneal vascularization, tarsal abnormalities, bulbar hyperemia, limbal hyperemia, or any other abnormality of the cornea that would contraindicate contact lens wear.
• Any corneal infiltrates or any corneal scarring or neovascularization within the central 5mm of the cornea.
• Keratoconus or other corneal irregularity.
• Aphakia or amblyopia.
• Have undergone corneal refractive surgery or any anterior segment surgery.
• Abnormal lacrimal secretions.
• Has diabetes.
• Known/reported infectious disease (e.g., hepatitis, tuberculosis) or an immunosuppressive disease (e.g., HIV).
• History of chronic eye disease (e.g. glaucoma).
• Pregnant or lactating or planning a pregnancy at the time of enrolment.
• Participation in any concurrent clinical trial or in last 30 days.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Test solution; A Multi-purpose soft contact lens care solution containing polyaminopropyl biguanide, polyquaternium-2.	Device: Test solution; A Multi-purpose soft contact lens care solution containing polyaminopropyl biguanide, polyquaternium-2.
Active Comparator: Control solution; A Multi-purpose soft contact lens care solution containing polyaminopropyl biguanide, polyquaternium-1.	Device: Control solution; A Multi-purpose soft contact lens care solution containing polyaminopropyl biguanide, polyquaternium-1.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Comfort	Subjective comfort(during the day). Subject grading comfort of lenses 0-10 (Higher scores indicates the subjects greater comfort with the lenses.)	Up to 4 weeks
Visual Acuity (VA)	Monocular and binocular high contrast Visual Acuity (VA) was measured at each visit and evaluated using a LogMAR VA Chart where the size of the letters become increasingly smaller from the top of the chart to the bottom of the chart. On this scale, the minimum VA (Worst achievable) is +1.00 LogMAR and the maximum value (Best achievable) is -0.30 LogMAR. Each line of the chart (a total of five letters per line) is equivalent to -0.10 LogMAR and each letter read is equivalent to -0.02. The lower the score/measurement , indicate a better VA obtained. Participants were positioned at a distance of three meters from the eye chart and asked to start reading letters from the top line and to continuing reading letters until they are unable to correctly identify three letters on any given line. The Visual Acuity was recorded to the nearest letter.	Visual Acuity was assessed for all participants after 2 weeks from day of dispensing lens solution and then again at the final evaluation at the 1 month visit.
Lens Surface Wetting	Lens surface wettability rated on the appearance of the lens surface and the drying time viewed with a slit lamp under low magnification. 0-4 scale (4 = Excellent)	Up to 4 weeks
Film Deposits	Any film deposits (protein/lipid) attached to the front surface of the lens. Scan the entire lens surface (10- 20X) for the presence of deposits. 0-4 (4= Heavy film)	Up to 4 weeks
Corneal Staining	Assessed using a slit lamp by sector with fluorescein, blue light, yellow filter and full beam using a medium magnification. Cornea staining will be assessed by sector (Central, Nasal, Temporal, Inferior, Superior) using a 0-4 scale where 0-4 is the total corneal staining score and higher staining score indicates a worse outcome.	Up to 4 weeks
Limbal Hyperemia	Assessed using slit lamp with white light, low-medium magnification. 0-4 ( 4= Severe)	Up to 4 weeks
Bulbar Hyperemia	Assessed using slit lamp with white light, low-medium magnification 0-4 ( 4= Severe)	Up to 4 weeks

Collaborators and Investigators

• Sponsor: OTE North America
• Collaborators: Visioncare Research Ltd.
• Investigators: Principal Investigator: Frances L Nicklin, Bsc, MCOptom, Visioncare Research Ltd.

Study record dates

Study Major Dates

• Study Start (Actual): August 14, 2017
• Primary Completion (Actual): November 17, 2017
• Study Completion (Actual): December 20, 2017

Study Registration Dates

• First Submitted: September 8, 2017
• First Submitted That Met QC Criteria: September 8, 2017
• First Posted (Actual): September 11, 2017

Study Record Updates

• Last Update Posted (Actual): March 26, 2021
• Last Update Submitted That Met QC Criteria: March 2, 2021
• Last Verified: March 1, 2021

More Information

Terms related to this study

• Keywords: Multipurpose Contact Lens Care System
• Additional Relevant MeSH Terms: Eye Diseases; Refractive Errors; Hyperopia; Pharmaceutical Solutions
• Other Study ID Numbers: OTES-3301

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: No